Objective: Ibrutinib is an irreversible inhibitor of Bruton tyrosine kinase (BTK) in B lymphocytes as well as other kinases including interleukin-2-inducible T-cell kinase (ITK) in CD4+ Th2 regulatory T cells. Increased infections have been observed in patients taking ibrutinib. The overall incidence has not been systematically evaluated.
CLL and high-risk CLL with deletion 17p (all lines of therapy) in 2014, Waldenström's macroglobulinemia (WM) in 2015, upfront therapy for CLL in 2016, and relapsed or refractory marginal zone lymphoma (MZL) in 2017. 3 As a result of its broad indication, oral route of administration, relative tolerability, and overall favorable side effect profile, ibrutinib has seen widespread adoption in clinical practice, especially in the treatment of elderly patients who would be unlikely to tolerate conventional cytotoxic chemotherapy. As with many other targeted agents for chronic diseases, the duration of ibrutinib administration is indefinite.
Therapy continues until the development of drug intolerance, disease progression, or death. This differs from other common indolent NHL regimens such as bendamustine-, fludarabine-, and/or rituximab-based regimens where a series of cytotoxic chemotherapy cycles is routinely followed by a period of observation. Although already commonly used in general hematology practice, the side effects of this therapeutic agent have not been fully characterized. While the associations of ibrutinib with bleeding and atrial fibrillation have been well described, significant but uncommon off-target effects of the tyrosine-protein kinase inhibitor such as ventricular arrhythmias continue to emerge. 4 Disease progression, adverse events (AE), and serious adverse events (SAE) have been the most common reasons for drug discontinuation, 5 with 62% of non-relapse-related discontinuations attributed to infections in one retrospective study. 6 Other unique toxicities have been identified, including ibrutinib-induced pneumonitis 4 and increased opportunistic infections (OIs) such as pneumocystis jirovecii pneumonia (PJP). 7 Increased infections and OIs in patients taking ibrutinib may reflect additional untoward effects of this targeted therapy. The role of BTK in multiple immune cells as well as concurrent inhibition of interleukin-2-inducible T-cell kinase (ITK) raises concerns for impaired host antimicrobial defense with ibrutinib use. 1 Reflecting on our own experience with invasive cryptococcal pneumonia in a patient with relatively preserved CD4+ T-cell counts taking ibrutinib, we sought to define the rate of infectious toxicities with a focus on pneumonia through a systematic review of prospective trials.
| METHODS
A search of the published literature and conference abstracts was conducted using PubMed, Google Scholar, and HemOnc.org. 8 Publications up to July 1, 2017, were included for evaluation. All prospective trials utilizing ibrutinib for the treatment of lymphoid malignancies were reviewed for inclusion in the analysis. Trials in which ibrutinib was used in the treatment of solid oncologic tumors, rheumatologic diseases, graft-versus-host disease, or maintenance therapy following allogeneic stem cell transplantation were excluded.
All studies which met the inclusion criteria were reviewed for infectious AEs, according to grade by the Common Terminology Criteria for Adverse Events version 4.03 (CTCAE). 9 Those studies which met the inclusion criteria but had insufficient data for analysis were fully reviewed but excluded in the final tables and analysis. Trials including only higher grade events (ie, CTCAE grade 3 or higher) affecting a certain number of enrolled patients (eg, more events. For the studies in which ibrutinib was compared with other standard treatments or combined with another study treatment,
we included data only from those patients treated on the ibrutinibcontaining study arm(s). We generally restricted the analysis to patients who received the drug (ie, on an intention-to-treat basis). We conducted our review in accordance with the PRISMA Statement. were reviewed and approved by the senior author of this report, who also adjudicated discrepancies arising from the initial independent reviews. For studies with an initial publication followed by subsequent reports of updated data, the initial data on infectious toxicities were used, unless one or the other did not include specific toxicity data, or a more comprehensive report was provided in a long-term follow-up publication. In these cases, the most complete toxicity report was used 
| RESULTS

| Search results
We identified 929 publications using PubMed, >11 000 from Google Scholar, as well as 772 from major international meeting abstract collections using the terms "ibrutinib" and "PCI-32765" (Figure 1 ). (Tables 1 and 2 ).
| Infectious toxicities in studies and trials
Infectious complications were reported in 92% (44/48) of trials with sufficient data for the final analysis. Table 1 and Table 2 summarize findings for those studies investigating ibrutinib as a single agent, or in combination with one or more other antineoplastics, respectively. One single-agent trial 24 and Aspergillus species (Table 3) . Some infectious AEs appeared to develop with prolonged use of the drug as noted in long-term follow-up studies, where they were reported as new events in the original study population. 15 
| DISCUSSION
In this systematic analysis of all prospective trials of ibrutinib use in hematologic malignancies, we found more than half of all patients experienced an infection while taking ibrutinib. The overall rates were similar between the 2 cohorts with 56% of patients receiving monotherapy and 52% of patients receiving combination therapy experiencing an infectious adverse event. Fatal episodes of pneumonia (70) 47 (24) 6 (3) 33 (17) 20 (10) 4 (2) 12 (6) Burger (28) 14 (10) 1 (1) - (7) 1 (1) T A B L E 2 Trials using ibrutinib in combination therapy 4 (10) 20 (50) 2 (5) 4 (10) 8 ( (77) 137 (47) 5 (2) 47 (16) 31 (11) 1 (0) 20 (7) Younes, et al - (55) - (25) 1 (5) - (15) 1 (5) 3 (15) Jaglowski, et al (72) 12 (18) 4 (6) 17 (25) 12 (18) 3 (4) 6 (9) Amaya-Chanaga, et al (38) 4 (7) 1 (2) 4 (7) 2 ( 34 (68) 6 (12) 1 (2) 2 (4) 2 ( (17) 11 (61) 9 (50) 2 (11) 8 (44) Total ( survival. 66 BTK is also found in neutrophils, monocytes, and macrophages where it mediates pathways involving innate and adaptive immunity. [67] [68] [69] The nuclear factor of activated T cells (NFAT) is BTK dependent and plays a key role in the macrophage inflammatory response to Aspergillus fumigatus. 67 Interference in BTK and ITK signaling pathways within these immune cells has been suggested as a mechanism by which ibrutinib may predispose patients to increased infections ( Figure 2 ). This trial also provided one of the most detailed toxicity reporting supplements among all of the reviewed publications likely accounting for the increased events between publications and the overall high rate of infectious AEs. Discrepancies between initial published response rates for cancer therapeutics in abstract form and subsequent response rates reported in peer-reviewed journals have been previously identified in oncology trials. 73 Comparison studies between abstracts and final publications have noted omission of toxicities in up to 18.5% of abstracts. 74 In this review, infectious adverse event data were often sparse or not reported at all in meeting abstracts with 62% (63/102) of 
